Clinical Trials Logo

Clinical Trial Summary

The study is to be performed in public health facilities in Central and West Africa where Pyramax will be used as treatment of uncomplicated malaria episodes, including repeat episodes. The study is to assess the safety of Pyramax, particularly in patients with underlying liver function abnormalities, in patients who have co-morbid conditions, such as HIV, and also in very small children (<1 year of age).


Clinical Trial Description

This is a non-comparative Cohort Event Monitoring study. The study will assess the safety of Pyramax in terms of the evaluation and identification of the hepatic safety events in a sub group of patients enrolled with liver function tests (LFT)s >2x upper limit of normal (ULN) from blood taken immediately prior to treatment without any clinical signs or symptoms of hepatotoxicity and with signs and symptoms of uncomplicated malaria confirmed by a Rapid Diagnostic Test (RDT) or microscopy (thick blood smear). The study will compare the clinical hepatic safety of Pyramax between a cohort of patients enrolled with LFTs >2xULN and a cohort of patients enrolled with normal LFTs matched for demographic characteristics.

An estimated 8,572 malaria episodes are to be recruited to provide 120 malaria episodes in patients with baseline raised LFTs >2xULN for follow up of liver function. A cohort of at least 2% of children who are <1 year of age will be included for monitoring of liver function. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03201770
Study type Interventional
Source Shin Poong Pharmaceutical Co. Ltd.
Contact Jang Sik Shin
Phone +82-2-2189-3468
Email jsshin@shinpoong.co.kr
Status Recruiting
Phase Phase 4
Start date June 22, 2017
Completion date December 2019

See also
  Status Clinical Trial Phase
Recruiting NCT03511443 - Evaluation of the Performance of a hsRDT Versus cRDT in Reactive Case Detection of Malaria Infections N/A
Not yet recruiting NCT03580824 - A Study to Determine if a New Malaria Vaccine is Safe and Induces Immunity Among Kenyan Adults, Young Children and Infants Phase 1/Phase 2
Completed NCT01992900 - A Pharmacokinetic/Pharmacodynamic Study of Eurartesim Dispersible Formulation in Infants With P.Falciparum Malaria Phase 2
Recruiting NCT03454048 - Controlled Human Malaria Infection Model for Evaluation of Transmission-blocking Interventions - Study 2 N/A
Active, not recruiting NCT03138096 - Safety and Protective Efficacy of Pb(PfCS@UIS4) Phase 1/Phase 2
Active, not recruiting NCT03176719 - Non-specific Effects of Vaccination on Mortality and Morbidity
Completed NCT03241901 - "Prolonging the Therapeutic Life Span of Artemisinin-based Combination Therapies (ACT) in Bagamoyo District, Tanzania" Phase 4
Recruiting NCT03178643 - Enhancing Preventive Therapy of Malaria In Children With Sickle Cell Anemia in East Africa (EPiTOMISE) Phase 4
Not yet recruiting NCT03640403 - Intermittent Preventive Treatment to Shrink the Malaria Reservoir and relaTed Morbidities by Targeting School Children in Regions With Different Malaria Endemicities Phase 4
Withdrawn NCT03195387 - Chemoprotective Activity of MMV390048 in PfSPZ Challenge Model Phase 1
Recruiting NCT03420053 - Study to Evaluate Safety, Immunogenicity and Efficacy of PfSPZ Vaccine in HIV Negative and HIV Positive Tanzanian Adults Phase 1
Completed NCT02987270 - Evaluation of Community-based Mass Screening and Treatment for Malaria in Western Kenya Phase 3
Completed NCT00378625 - Efficacy, Effect on Gametocytes and Tolerability of the Addition of Artesunate to Amodiaquine in Colombia Phase 3
Active, not recruiting NCT03143218 - Seasonal Malaria Vaccination (RTS,S/AS01) and Seasonal Malaria Chemoprevention (SP/AQ) Phase 3
Recruiting NCT03435874 - Safety and Immunogenicity of ChAd63 RH5 and MVA RH5 in Adults, Young Children and Infants Living in Tanzania Phase 1